Global and cardiovascular mortality and risk factors in patients under hemodialysis treatment;Mortalidad global y cardiovascular y factores de riesgo de pacientes en hemodiálisis

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 2, 2010, Pages

  Almeida, Fátima Aparecida A ^a   Machado, Felipe Carrhá ^a   Moura Jr , José Andrade ^a   Guimarães, Armênio Costa ^a  

^a ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

Author keywords

Kidney failure chronic; Letality cardiovascular diseases; Mortality; Renal dialysis

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK FACTOR; SURVIVAL RATE;

EID: 77951980313     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sociedade Brasileira de Nefrologia. Censos. [Acesso em 2007 jul 7]. Disponível em: http://www.sbn.org.br/censos.htm.
2. Silva Jr ACC, Abensur H, Lotaif LD, Amodeo C, Piegas LP. Novos fatores de risco cardiovascular. Rev Soc Cardiol Estado de São Paulo. 2007; 17 (1): 50-59
3. Canziani ME. Doenças cardiovasculares na doença renal crônica. J Bras Nefrol. 2005; 26 (supl. 1): 20-21
4. Gasperin CA, Germiniani H, Facin AR, Souza AM, Cunha CLP. Análise dos critérios eletrocardiográficos para determinação da sobrecarga ventricular esquerda. Arq Bra Cardiol. 2002; 78 (1): 59-71.
5. Isek K, Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int. 2007; 72: 54-59 (Pubitemid 47609056)
6. Zalunardo N, Levin A. Anemia and the heart in chronic kidney disease. Semin Nephrol. 2006; 26: 290-295 (Pubitemid 44722448)
7. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int. 2004; 65 (2): 626-633 (Pubitemid 38130658)
8. Dogra G, Irish A, Chan D, Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis. 2006; 48: 926-934 (Pubitemid 44895366)
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-2752
10. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998; 54: 561-569
11. Chertow GM, Burke SM, Dillon MA, Slatolposky E, for the RenaGel Study Group. Long-term effects of sevelamer hydrochloride on calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant. 1999; 14: 2907-2914
12. Carvalho AB, Cuppari L. Controle da hiperfosfatemia na DRC. J Bras Nefrol. 2008; 30 (supl 2): 4-8.
13. Delmez, J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, et al. A randomized, double-blind crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007; 68 (6): 386-391 (Pubitemid 350258767)
14. Shantouf R, Budoff MJ, Ahmadi N, Tiano J, Flores F, Kalantar-Zadeh K. Effects of sevelamer and calcium-based phosphate binders on lipid an inflammatory markers in hemodyalisis patients. Am J Nephrol. 2008; 28: 275-279